Elixir

Loading Examiner's Profile.

Last updated on - 11 Mar, 2025

Generic: Naloxegol

Revenue: $0.45 Billion

Source: Verified Market Reports

Year: 2022

Country	Generic/Branded	Drug Name	Revenue	Source	Year
US	Branded	Movantik (U.S) / Moventig (Europe)	$200 Million	Grunenthal Press Release	2023
CA	Branded	Movantik	$0.372 Million	Knight Therapeutics Announcement	2016
EP	Branded	Moventig	$70 Million	European Pharmaceutical Review	2016

Product	Medicine	Therapeutic Area	Common Name	Marketing Authorisation Date	Data Exclusivity Expiration Date	Market Exclusivity Expiration Date	Company Name	Orphan Drug